Geode Capital Management
NAVB

Geode Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Geode Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-368,830
Closed -$33.1K – 4820
2023
Q3 		$33.1K Buy
368,830
+267,832
+265% +$24.9K ﹤0.01% 4525
2023
Q2 		$9.29K Sell
100,998
-3,621
-3% -$577 ﹤0.01% 4723
2023
Q1 		$27.2K Hold
104,619
– – ﹤0.01% 4647
2022
Q4 		$21K Hold
104,619
– – ﹤0.01% 4763
2022
Q3 		$26K Hold
104,619
– – ﹤0.01% 4880
2022
Q2 		$75K Buy
104,619
+7,413
+8% +$6.3K ﹤0.01% 4680
2022
Q1 		$76K Hold
97,206
– – ﹤0.01% 4729
2021
Q4 		$97K Hold
97,206
– – ﹤0.01% 4745
2021
Q3 		$170K Hold
97,206
– – ﹤0.01% 4513
2021
Q2 		$177K Buy
97,206
+22,064
+29% +$39K ﹤0.01% 4386
2021
Q1 		$151K Hold
75,142
– – ﹤0.01% 4202
2020
Q4 		$161K Hold
75,142
– – ﹤0.01% 3947
2020
Q3 		$202K Buy
75,142
+36,163
+93% +$130K ﹤0.01% 3717
2020
Q2 		$153K Buy
38,979
+2,970
+8% +$5.68K ﹤0.01% 3740
2020
Q1 		$27K Hold
36,009
– – ﹤0.01% 4013
2019
Q4 		$45K Hold
36,009
– – ﹤0.01% 4104
2019
Q3 		$24K Hold
36,009
– – ﹤0.01% 4133
2019
Q2 		$22K Sell
36,009
-1
-0% -$2 ﹤0.01% 4157
2019
Q1 		$99K Hold
36,010
– – ﹤0.01% 3899
2018
Q4 		$73K Hold
36,010
– – ﹤0.01% 3921
2018
Q3 		$166K Hold
36,010
– – ﹤0.01% 3807
2018
Q2 		$164K Hold
36,010
– – ﹤0.01% 3767
2018
Q1 		$259K Hold
36,010
– – ﹤0.01% 3613
2017
Q4 		$258K Hold
36,010
– – ﹤0.01% 3592
2017
Q3 		$298K Hold
36,010
– – ﹤0.01% 3533
2017
Q2 		$367K Hold
36,010
– – ﹤0.01% 3467
2017
Q1 		$415K Hold
36,010
– – ﹤0.01% 3376
2016
Q4 		$452K Hold
36,010
– – ﹤0.01% 3302
2016
Q3 		$659K Hold
36,010
– – ﹤0.01% 3143
2016
Q2 		$382K Sell
36,010
-5,278
-13% -$104K ﹤0.01% 3332
2016
Q1 		$779 Buy
41,288
+480
+1% +$9.24K ﹤0.01% 3016
2015
Q4 		$1.08M Buy
40,808
+1,705
+4% +$59.2K ﹤0.01% 2878
2015
Q3 		$1.78M Buy
39,103
+1,779
+5% +$67.1K ﹤0.01% 2518
2015
Q2 		$1.2M Buy
37,324
+177
+0.5% +$5.14K ﹤0.01% 2808
2015
Q1 		$1.18M Hold
37,147
– – ﹤0.01% 2776
2014
Q4 		$1.4M Buy
37,147
+2,475
+7% +$68.1K ﹤0.01% 2638
2014
Q3 		$915K Buy
34,672
+1,161
+3% +$30.7K ﹤0.01% 2828
2014
Q2 		$991K Buy
33,511
+1,749
+6% +$56.6K ﹤0.01% 2813
2014
Q1 		$1.18M Buy
31,762
+977
+3% +$37.1K ﹤0.01% 2681
2013
Q4 		$1.27M Buy
30,785
+4,587
+18% +$179K ﹤0.01% 2563
2013
Q3 		$1.39M Buy
26,198
+817
+3% +$47.6K ﹤0.01% 2394
2013
Q2 		$1.35M Buy
+25,381
New +$1.27M ﹤0.01% 2281

Other funds holding NAVB

BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

Geode Capital Management's NAVB Position: Q4 2023 in Review

Geode Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 368,830 shares — an estimated $33.1K sold.

Geode Capital Management first reported a position in NAVB in Q2 2013 and held it in 42 quarters. The position peaked at $1.78M in Q3 2015. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

  • Geode Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
  • Geode Capital Management sold 368,830 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $33.1K.
  • Geode Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 42 quarters.
  • Geode Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $1.78M in Q3 2015.
  • 4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on Geode Capital Management's 13F filing for Q4 2023, filed 13 Feb 2024.